Jhanelle Gray

基本信息

Career Trajectory

Bio

Dr. Gray is actively involved as a member of the MCC Scientific Leadership Council and Clinical Research Action Committee. Globally she is the American Society for Clinical Oncology (ASCO) 2022 Meeting Education Program Chair-elect while also serving as a member of the ASCO Lung Scientific Program Committee, IASLC Women in Thoracic Oncology Working Group and Southwest Oncology Group (SWOG) Lung Working Group.

Research Interests

Papers共 408 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation after Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer

JOURNAL OF THORACIC ONCOLOGYno. 1 (2025): 109-118

Cited0Views0WOSBibtex

Abstract A021: Evolutionary Immunotherapy in NSCLC: an Integrated Approach

Sandhya Prabhakaran,Taylor M. Bursell,Kimberly Luddy, Julian Pineiro,Rafael Bravo,Jeffrey West, Megan Johnson,Mark Robertson-Tessi,Amer A. Beg,Jhanelle E. Gray,Scott Antonia,Robert A. Gatenby,Alexander R. A. Anderson

Cancer Research（2024）

Cited0Views0Bibtex

Comparison of Small Cell Lung Cancer Transcriptional Factor Expression by Immunohistochemistry, Multiplex Immunofluorescence, and a Targeted RNA Expression Panel

Hilal Ozakinci,Aileen Alontaga,Jonathan V. Nguyen,Carlos M. Moran Segura,Daryoush Saeed-Vafa,Jhanelle Gray,Eric Haura,Alberto A. Chiappori,Theresa Boyle

CANCER RESEARCHno. 6 (2024)

Cited0Views0Bibtex

Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action

M.-L. Meyer,S. Peters,T.S. Mok, S. Lam, P.-C. Yang, C. Aggarwal,J. Brahmer,R. Dziadziuszko,E. Felip, A. Ferris,P.M. Forde,J. Gray, L. Gros, B. Halmos,R. Herbst, P.A. Jänne,B.E. Johnson, K. Kelly, N.B. Leighl,S. Liu

Annals of Oncology (2024)

Cited0Views0WOSBibtex

Supplementary Figure 1 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

crossref（2024）

Cited0Views0Bibtex

A Phase I/II Study of Davutamig (REGN5093), a METxMET Bispecific Antibody, in Patients with MET-altered, Advanced Non-Small Cell Lung Cancer (ansclc): Trial in Progress Update

M-j. Ahn,B. C. Cho,T. M. Kim,J-y. Han, C. Kim,B. Shim, A. Drilon,G. Blumenschein,L. Villaruz,J. E. Gray,J-l. Pujol,H. Lena,D. Moro-Sibilot, J. Perez, D. A. Modi, J. S. Park, S. Patel, S. Li, E. Kim,H. Magnan

ANNALS OF ONCOLOGY (2024): S1673-S1674

Cited0Views0Bibtex

Pembrolizumab with or Without Maintenance Olaparib for Metastatic Squamous Non–Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy

Maximilian Hochmair,Michael Schenker,Manuel Cobo Dols,Tae Min Kim,Ozgur Ozyilkan, Maria Smagina,Leonova Viktoriya,Terufumi Kato, Alexander Fedenko,Flavia De Angelis,Achim Rittmeyer,Jhanelle E. Gray,Alastair Greystoke,Himani Aggarwal,Qinlei Huang, Bin Zhao,Humberto Lara-Guerra,Ernest Nadal

Journal of Thoracic Oncology (2024)

Cited0Views0Bibtex

Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

CLINICAL CANCER RESEARCHno. 8 (2024): 1655-1668

Cited4Views0WOSBibtex

Supplementary Figure 8 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 408 篇Author StatisticsCo-AuthorSimilar Experts